Compares two heart-bypass machine methods during heart surgery in adults
Compares a minimally invasive bypass circuit with standard bypass in adults having heart surgery.
Plain-language title generated from the registry record
Registry title: MiECC Versus Conventional Cardiopulmonary Bypass in Cardiac Surgery (MiECS)
Key facts
- Where
- Toronto, CanadaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults having planned or urgent heart surgery (bypass grafting, aortic valve replacement, or both) using a heart-lung machine, to compare two types of machine.
- Age
- 18 to 85 years
- Sex
- All sexes can join.
- Disease stage
- Coronary artery disease or aortic valve stenosis needing elective or urgent coronary artery bypass grafting (CABG), aortic valve replacement (AVR) or CABG+AVR surgery, without circulatory arrest.
Main reasons for not taking part
- Emergency or salvage operation
- Major aortic surgery, for example aortic root replacement
- Cannot or will not accept blood product transfusion, for example Jehovah's Witnesses
- Inherited or acquired platelet, red cell or clotting disorders (iron deficiency anaemia is allowed)
- Unable to give informed consent, for example because of learning or language difficulties
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Source: NCT05487612, who can take part
Where in Canada
- Perfusion Services University Health Network, Toronto General HospitalToronto, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Aristotle University Of Thessaloniki
- Trial code
- NCT05487612
- Record updated
- 30 March 2026
- Original description
MiECS is one of the largest multicentre randomised controlled trials on extracorporeal circulation conducted under the auspices of Minimal Invasive Extracorporeal Technologies International Society (MiECTiS). It is designed to ultimately address the emerging effectiveness of MiECC systems in the light of modern perfusion practice worldwide. The primary hypothesis is that MiECC, as compared to conventional CPB (cCPB), reduces the proportion of patients experiencing serious perfusion-related postoperative morbidity after cardiac surgery. The study will be led by the Clinical Research Unit of the Special Unit for Biomedical Research and Education (SUBRE), Aristotle University of Thessaloniki School of Medicine in Greece (AUSoM) with Chief Investigator Professor Kyriakos Anastasiadis, who is a key-opinion-leader in the field of MiECC, founder and Executive Board of MiECTiS.Read full original descriptionShow less
Minimally Invasive Extracorporeal Circulation Versus Conventional Cardiopulmonary Bypass in Patients Undergoing Cardiac Surgery (MiECS): a Randomised Controlled Trial
MiECS is one of the largest multicentre randomised controlled trials on extracorporeal circulation conducted under the auspices of Minimal Invasive Extracorporeal Technologies International Society (MiECTiS). It is designed to ultimately address the emerging effectiveness of MiECC systems in the light of modern perfusion practice worldwide. The primary hypothesis is that MiECC, as compared to conventional CPB (cCPB), reduces the proportion of patients experiencing serious perfusion-related postoperative morbidity after cardiac surgery. The study will be led by the Clinical Research Unit of the Special Unit for Biomedical Research and Education (SUBRE), Aristotle University of Thessaloniki School of Medicine in Greece (AUSoM) with Chief Investigator Professor Kyriakos Anastasiadis, who is a key-opinion-leader in the field of MiECC, founder and Executive Board of MiECTiS.
Inclusion: All patients undergoing any elective or urgent coronary artery bypass grafting (CABG), aortic valve replacement (AVR) or CABG+AVR surgery using extracorporeal circulation without circulatory arrest.
Exclusion: Requirement for major aortic surgery (e.g. aortic root replacement); Congenital or acquired platelet, red cell or clotting disorders (patients with iron deficient anaemia will not be excluded); Requirement for emergency or salvage operation; Contraindication or objection (e.g. Jehovah's Witnesses) to transfusion of blood products; Inability to give informed consent for the study (e.g. learning or language difficulties).